首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Signaling by the human serotonin(1A) receptor is impaired in cellular model of Smith-Lemli-Opitz Syndrome.
【24h】

Signaling by the human serotonin(1A) receptor is impaired in cellular model of Smith-Lemli-Opitz Syndrome.

机译:Smith-Lemli-Opitz综合征的细胞模型中,人血清素(1A)受体的信号传导受到损害。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The Smith-Lemli-Opitz Syndrome (SLOS) is a congenital and developmental malformation syndrome associated with defective cholesterol biosynthesis. SLOS is clinically diagnosed by reduced plasma levels of cholesterol along with elevated levels of 7-dehydrocholesterol (and its positional isomer 8-dehydrocholesterol) and the ratio of their concentrations to that of cholesterol. Since SLOS is associated with neurological deformities and malfunction, exploring the function of neuronal receptors and their interaction with membrane cholesterol under these conditions assumes significance. We have earlier shown the requirement of membrane cholesterol for the ligand binding function of an important neurotransmitter G-protein coupled receptor, the serotonin(1A) receptor. In the present work, we have generated a cellular model of SLOS using CHO cells stably expressing the human serotonin(1A) receptor. This was achieved by metabolically inhibiting the biosynthesis of cholesterol, utilizing a specific inhibitor (AY 9944) of the enzyme required in the final step of cholesterol biosynthesis. We utilized this cellular model to monitor the function of the human serotonin(1A) receptor under SLOS-like condition. Our results show that ligand binding activity, G-protein coupling and downstream signaling of serotonin(1A) receptors are impaired in SLOS-like condition, although the membrane receptor level does not exhibit any reduction. Importantly, metabolic replenishment of cholesterol using serum partially restored the ligand binding activity of the serotonin(1A) receptor. These results are potentially useful in developing strategies for the future treatment of the disease since intake of dietary cholesterol is the only feasible treatment for SLOS patients.
机译:Smith-Lemli-Opitz综合征(SLOS)是与胆固醇生物合成缺陷相关的先天性和发育畸形综合征。临床上可通过降低血浆胆固醇水平,升高7-脱氢胆固醇(及其位置异构体8-脱氢胆固醇)及其浓度与胆固醇之比来诊断SLOS。由于SLOS与神经畸形和功能障碍有关,因此在这些条件下探索神经元受体的功能及其与膜胆固醇的相互作用具有重要意义。我们之前已经显示出膜胆固醇对于重要的神经递质G蛋白偶联受体血清素(1A)受体的配体结合功能的需求。在当前的工作中,我们已经使用稳定表达人血清素(1A)受体的CHO细胞生成了SLOS细胞模型。这是通过利用胆固醇生物合成最后一步所需的酶的特异性抑制剂(AY 9944)来代谢抑制胆固醇的生物合成来实现的。我们利用这种细胞模型来监测人类的血清素(1A)受体在SLOS样条件下的功能。我们的结果表明,尽管膜受体水平没有降低,但在SLOS样条件下,血清素(1A)受体的配体结合活性,G蛋白偶联和下游信号均受到损害。重要的是,使用血清的胆固醇代谢补充可以部分恢复5-羟色胺(1A)受体的配体结合活性。这些结果可能对制定该疾病的未来治疗策略很有用,因为摄入胆固醇的饮食是SLOS患者唯一可行的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号